J&J’s Company Split Action May Trigger Series of Biochemical and Pharma Corporate Restructurings
Johnson & Johnson (JNJ) is the latest big, diversified company to announce it is breaking into smaller parts.
It plans to spin off its prescription drug and medical device brand from its consumer products.
The planned separation would create two global leaders that are better positioned to deliver improved health outcomes for patients and consumers through innovation, pursue more targeted business strategies and accelerate growth.
Following the planned separation, the new Johnson & Johnson would remain the world’s largest and most diverse healthcare company and continue its commitment to lead in global healthcare R&D and innovation, with a portfolio that blends its strong Pharmaceutical and Medical Device capabilities focused on advancing the standard of care through innovation and technology.
But Johnson & Johnson's decision to split into two companies may just be the tip of the iceberg. Merck & Co. (MRK) could also look to spin off its animal health unit after bulking it up, Oppenheimer & Co. analyst Jared Holz said in an interview on Friday on CNBC.
U.S. Foreign Trade Deficit Trimmed in October but Remains Historically Elevated
According to the U.S. Department of Commerce, in seasonally adjusted terms, the U.S. foreign trade deficit slowed down to a monthly pace of 14.6% to reach a still-alarming $82.9 billion.
China Becomes Concerned about “Quasi-Stagflation” as Developers Face Mounting Troubles
According to Bloomberg, Liu Shijin, an adviser to the People’s Bank of China, the country’s economy may face a period of “quasi-stagflation” with relatively slow growth and excessively high producer-price inflation.
Largest U.S. Department Stores Upbeat on Upcoming Holiday Shopping Season
Macy's (M) stocks rallied after reporting comparable sales increased 37.2% on a comparable basis in Q3 and were up 35.6% on an owned-plus-licensed basis during the quarter.
